is on a mission to change the future for millions of cancer patients. We are developing novel therapies that target the most aggressive cancer cells through a first-in-class mechanism of action, and demonstrate a high level of selectivity for the reprogrammed cancer mitochondria.
Penrose has developed a novel Mitochondrial Modifying Agent (MMA) therapeutic platform designed to generate therapies that kill some of the most difficult to treat cancers. Highly selective oral small molecules target cancer mitochondria in a cooperative fashion, leading to necrotic cell death.
Chief Executive Officer
Mr. de Souza has decades of leadership experience in supporting advancements in healthcare and a strong track record in building and leading organizations.
Chief Medical Officer
Dr. Gill is a practicing cardio-oncologist with extensive experience in healthcare management and is a founding member of Penrose TherapeuTx.
Chief Development Officer
Dr. Desai is a hematologist and medical oncologist with three decades of clinical oncology. He is a leader in oncology clinical drug development across all classes of medication and phases of development.
Director of Chemistry, Manufacturing, and Controls
Chief Financial Officer & Chief Operating Officer
Mr. Schutt has over a decade of experience in balance sheet optimization, corporate finance, investment banking, and business development with publicly traded and privately held financial institutions ranging from $250 million to $25 billion in assets. He is also a founding member of Penrose TherapeuTx.